Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.

Cancers (Basel) · 2022 · PMC9455040 · PMID 36077644

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

OS was also different according to the CPSS-Mol-defined risk groups but these differences did not reach statistical significance: 85.1 months for low-risk patients; 64.3 months for intermediate-1 patients; 46.8 months for intermediate-2 patients; and 19.1 months for high-risk patients ( p = 0.09) ( Table 3 and Figure 3 C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.